Science Saturday: Researchers explore personalized approach to anti-obesity medications
Individualized medicine initiatives mainly focus on rare diseases or cancer. Little has been attempted to individualize treatment for noncommunicable chronic diseases such as obesity -- a chronic, relapsing disease, and a primary cause of Type 2 diabetes, fatty liver disease, cardiovascular disease and cancer. There are many obesity interventions, such as diets, devices, surgery and [...]
Dalton Trans., 2021, Advance Article DOI: 10.1039/D1DT01460A, PaperLiping Qiao, Jiangping Liu, Shi Kuang, Xinxing Liao, Junfeng Kou, Liangnian Ji, Hui Chao A mitochondria-targetedBODIPY-Ir(III) conjugate acted as a photoinduced ROS generator and exerted high oxidative lethality towards triple-negative breast cancer cells at an ultralow concentration under irradiation. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
But rates higher for infection - related cancers, such as liver and stomach cancers, and cervical cancer
Progression - free survival longer with T - DXd versus T - DM1 for HER2+ metastatic breast cancer previously treated with trastuzumab and taxane
FDA has approved Repatha (evolocumab) injection as an add-on treatment to diet alone or together with certain other therapies for patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH).
Findings seen for screening - detected breast cancer, but not interval cancer risk
You can say one thing for Professor Mark Haub: He knows how to make a lesson stick. Haub, who teaches nutrition at Kansas State University, wanted to prove to his students that weight loss is simply about calories. So, for 10 weeks, the professor proceeded to eat an 1,800-calorie diet consisting of a Twinkie every three hours. He also dined on Doritos, Little Debbies, sugary cereal and other junk food. When he started, Haub tipped the scales at 201 pounds, which for his height was considered overweight. By the end of his snack-food spree, he had lost 27 pounds, putting him at a svelte 174. The story went viral, with the me...
We describe a successfully diagnosed and treated CHL-PTLD stage IV pediatric patient, 8 years after liver transplantation. The patient was treated with standard CHL (Children’s Cancer Group 5942 group 3) chemotherapy, rituximab and reduction of immunosuppressant. The patient remains in complete remission after 3 years with stable graft function. To our best knowledge, this is the first pediatric case report of a successfully treated stage IV CHL-PTLD after a liver transplant.
Hepatitis-associated aplastic anemia (HAAA) has been reported in 23% to 33% of patients who received orthotopic liver transplantation (LT) for acute liver disease of unknown origin (nonviral hepatitis). In this situation, hematopoietic stem cell transplantation (HSCT) might be a curative option. Here the authors report on 6 patients who received HSCT after LT for nonviral HAAA hepatitis. The outcomes were interpreted in the context of recently reported immune suppressive therapy (IST) outcomes in 8 patients with HAAA and to HSCT outcomes in patients with HAAA who recovered from hepatitis without undergoing LT. All patients...
No abstract available
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Databases & Libraries | Diabetes | Diabetes Type 2 | Diets | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Heart | Liver | Liver Disease | Nutrition | Obesity | Rare Diseases | Science | Urology & Nephrology